Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study

Paul G. Richardson, MD, Philippe Moreau, MD, Andrzej J Jakubowiak, MD, PhD, Thierry Facon, MD, Sundar Jagannath, MD, Ravi Vij, MD, Donna E Reece, MD, Darrell J White, MD, Marc S Raab, MD, PhD, Lotfi Benboubker, MD, PhD, Jean-Francois Rossi, MD, PhD, Claire Tsao, PhD, John Fry, David Berman, MD, PhD, Anil K Singhal, MD, Sagar Lonial, MD

Blood (2010) 116 (21): 986.

https://doi.org/10.1182/blood.V116.21.986.986

Published: 2010

Journal Articles

Tanespimycin + Bortezomib Demonstrates Safety, Activity, and Effective Target Inhibition in Relapsed/Refractory Myeloma Patients: Updated Results of a Phase 1/2 Study.

Paul G. Richardson, MD, Asher A. Chanan-Khan, MD, Sagar Lonial, MD, Amrita Y. Krishnan, MD, Michael P. Carroll, MD, Maher Albitar, MD, Justin Kopit, PhD, David Berman, MD, PhD, Kenneth C. Anderson, MD

Blood (2009) 114 (22): 2890.

https://doi.org/10.1182/blood.V114.22.2890.2890

Published: 2009

Journal Articles

Tanespimycin Reverses Bortezomib-Induced Inhibition of Granulopoiesis.

Bruce D. Car, BVSc, PhD, DACVP, DABT, Oliver P. Flint, PhD, Jan Oberdoerster, PhD, DABT, Jennifer Price, William R. Foster, Brian Gemzik, PhD, David Berman, MD, PhD

Blood (2009) 114 (22): 3846.

https://doi.org/10.1182/blood.V114.22.3846.3846

Published: 2009

Journal Articles

Tanespimycin + Bortezomib in Relapsed/Refractory Myeloma Patients: Results From the Time-2 Study.

Ashraf Z. Badros, MD, Paul G. Richardson, MD, Maher Albitar, MD, Sundar Jagannath, MD, Stefano Tarantolo, MD, Jeffrey L. Wolf, MD, Marianne Messina, David Berman, MD, PhD, Kenneth C. Anderson, MD

Blood (2009) 114 (22): 1871.

https://doi.org/10.1182/blood.V114.22.1871.1871

Published: 2009

Journal Articles

Tanespimycin Prevents Bortezomib Toxicity and Preserves Neuronal Morphology in Primary Rat Dorsal Root Ganglion Cultures.

Oliver P. Flint, PhD, Jae Kwagh, Faye Wang, Frederic Moulin, Jan Oberdoerster, PhD, DABT, David Berman, MD, PhD, Bruce Car, BVSc, PhD, DACVP, DABT

Blood (2009) 114 (22): 2847.

https://doi.org/10.1182/blood.V114.22.2847.2847

Published: 2009

NARROW

Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study

Tanespimycin + Bortezomib Demonstrates Safety, Activity, and Effective Target Inhibition in Relapsed/Refractory Myeloma Patients: Updated Results of a Phase 1/2 Study.

Tanespimycin Reverses Bortezomib-Induced Inhibition of Granulopoiesis.

Tanespimycin + Bortezomib in Relapsed/Refractory Myeloma Patients: Results From the Time-2 Study.

Tanespimycin Prevents Bortezomib Toxicity and Preserves Neuronal Morphology in Primary Rat Dorsal Root Ganglion Cultures.

Email alerts

ASH Publications

American Society of Hematology

Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study

Tanespimycin + Bortezomib Demonstrates Safety, Activity, and Effective Target Inhibition in Relapsed/Refractory Myeloma Patients: Updated Results of a Phase 1/2 Study.

Tanespimycin Reverses Bortezomib-Induced Inhibition of Granulopoiesis.

Tanespimycin + Bortezomib in Relapsed/Refractory Myeloma Patients: Results From the Time-2 Study.

Tanespimycin Prevents Bortezomib Toxicity and Preserves Neuronal Morphology in Primary Rat Dorsal Root Ganglion Cultures.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only